export const modelCardData = {
  cardiovascular: {
    // Basic Information
    interventionName: "Cerner ASCVD Risk Calculator v2.1.3",
    developerName: "Oracle Cerner Corporation",
    developerContact: "Oracle Cerner Corporation\n2800 Rockcreek Parkway, North Kansas City, MO 64117\nEmail: clinical.ai@cerner.com\nPhone: 1-800-237-6371",
    fundingSource: "Oracle Corporation internal R&D funding in collaboration with American Heart Association Scientific Statements",
    valueOutput: "10-year atherosclerotic cardiovascular disease risk percentage (0-100%) with risk stratification categories (Low <5%, Borderline 5-7.4%, Intermediate 7.5-19.9%, High ≥20%)",
    outputType: "Prediction & Risk Classification",
    complianceBadge: "✓ ONC HTI-1 Compliant | 21st Century Cures Act",
    
    // Purpose of Intervention
    intendedUse: "Primary prevention cardiovascular risk assessment to inform statin therapy decision-making and lifestyle modification counseling in adults without existing cardiovascular disease",
    intendedPatientPopulation: "Adults aged 40-79 years without clinical atherosclerotic cardiovascular disease, diabetes, or LDL-C ≥190 mg/dL presenting for primary care evaluation",
    intendedUsers: "Licensed physicians, nurse practitioners, and physician assistants in primary care, internal medicine, family medicine, and cardiology practices",
    decisionMakingRole: "Informs & Augments",
    decisionMakingDesc: "Provides clinical decision support to inform and augment clinician judgment; does not replace clinical decision-making",
    
    // Cautioned Out-of-Scope Use
    criticalAvoidances: [
      "Emergency/Acute Settings: Not for use in emergency departments or acute care settings",
      "Pediatric Populations: Not validated for patients under 40 years of age",
      "Existing CVD: Not appropriate for patients with established coronary heart disease, stroke, or peripheral arterial disease",
      "Specific Conditions: Not for patients with familial hypercholesterolemia, Type 1 diabetes, or severe CKD",
      "Pregnancy: Not validated during pregnancy or lactation",
      "Non-US Populations: Derived from US cohorts; use caution in other populations"
    ],
    knownRisks: [
      "Algorithmic Bias: May underestimate risk in South Asian and Hispanic populations",
      "Data Currency: Based on cohorts from 1970s-2000s; modern treatment effects may differ",
      "Missing Variables: Does not include family history, coronary calcium scores, or inflammatory markers",
      "Population Shift: Performance may degrade as population demographics change",
      "Sole Decision-Making: Never use as the sole basis for treatment decisions",
      "Local Adaptation: May require local calibration for specific populations"
    ],
    
    // Development Details and Input Features
    trainingInclusion: "Adults 40-79 years; Complete risk factor data; Minimum 10-year follow-up; US-based cohorts",
    trainingExclusion: "Existing CVD at baseline; Missing critical variables; Non-fasting lipid measurements; Pregnancy during study",
    
    // USCDI v4 Data Elements
    uscdiElements: {
      race: { used: true, description: "White, Black/African American, Other" },
      ethnicity: { used: true, description: "Hispanic/Latino, Not Hispanic/Latino" },
      sex: { used: true, description: "Male, Female (biological sex at birth)" },
      dateOfBirth: { used: true, description: "For age calculation (40-79 years)" },
      language: { used: false, description: "Not included in risk calculation" },
      sexualOrientation: { used: false, description: "Not included in risk calculation" },
      genderIdentity: { used: false, description: "Not included in risk calculation" },
      socialDeterminants: { used: false, description: "Not included in current model version" },
      healthAssessments: { used: true, description: "Smoking status, diabetes status" }
    },
    
    // Demographic Representativeness
    demographicRepresentativeness: [
      { variable: "White Race", trainingData: "73.2%", usPopulation: "76.3%", representativeness: "Good" },
      { variable: "Black/African American", trainingData: "21.8%", usPopulation: "13.4%", representativeness: "Over-represented" },
      { variable: "Hispanic/Latino", trainingData: "8.4%", usPopulation: "18.5%", representativeness: "Under-represented" },
      { variable: "Female Sex", trainingData: "54.1%", usPopulation: "50.8%", representativeness: "Good" },
      { variable: "Age 40-59", trainingData: "67.2%", usPopulation: "62.1%", representativeness: "Good" }
    ],
    
    relevanceToDeployedSetting: "Training data derived from community-based cohorts representative of US primary care populations. Geographic diversity includes North, South, East, West regions. Socioeconomic diversity adequate for primary care settings.",
    
    fairnessApproach: "Race/ethnicity-specific calibration performed. Separate coefficients developed for demographic subgroups to ensure equitable performance across populations.",
    biasManagement: "Regular fairness audits across demographic subgroups. Stratified analysis by race, ethnicity, sex, and age. Continuous monitoring for performance disparities in deployment.",
    
    // External Validation
    externalDataSources: "Multi-Ethnic Study of Atherosclerosis (MESA), Women's Health Initiative (WHI), REasons for Geographic And Racial Differences in Stroke (REGARDS)",
    clinicalSettings: "Community-based primary care practices, academic medical centers, integrated health systems across 15 US states",
    externalTestingParty: "Independent validation by Duke Clinical Research Institute and American Heart Association Cardiovascular Disease in Women Committee",
    externalValidationProcess: "Prospective cohort validation with 10-year follow-up. Discrimination and calibration assessment across demographic subgroups. Real-world implementation studies in 6 health systems.",
    
    externalValidationDemographics: [
      { variable: "White Race", mesa: "41.2%", whi: "84.1%", regards: "58.3%" },
      { variable: "Black Race", mesa: "25.8%", whi: "9.2%", regards: "41.7%" },
      { variable: "Hispanic", mesa: "21.9%", whi: "4.1%", regards: "0.6%" },
      { variable: "Female", mesa: "52.8%", whi: "100%", regards: "55.1%" }
    ],
    
    // External Validation Sample Sizes
    externalValidationSampleSizes: {
      mesa: "6,814",
      whi: "8,090", 
      regards: "16,025"
    },
    
    // Performance Metrics
    internalValidationMetrics: {
      aurocValidity: "0.76",
      fairnessScore: "0.81",
      fairnessScoreDesc: "Min subgroup AUROC",
      calibration: "Good",
      calibrationDesc: "Hosmer-Lemeshow p=0.12",
      sensitivity: "72.4%",
      specificity: "68.9%",
      ppv: "8.2%"
    },
    
    externalValidationMetrics: {
      aurocValidity: "0.71",
      aurocValidityDesc: "External Cohorts",
      fairnessScore: "0.68",
      fairnessScoreDesc: "Min External AUROC",
      calibration: "Fair",
      calibrationDesc: "Some overestimation",
      publishedStudies: "3",
      publishedStudiesDesc: "Published Studies on Clinical Outcomes"
    },
    
    outcomeEvaluationReferences: [
      "Muntner P, et al. 'Validation of the 2013 ACC/AHA pooled cohort risk equations.' JAMA. 2014;311(14):1406-1415.",
      "DeFilippis AP, et al. 'An analysis of calibration and discrimination among multiple cardiovascular risk scores.' Ann Intern Med. 2015;162(4):266-275.",
      "Yadlowsky S, et al. 'Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk.' Ann Intern Med. 2018;169(1):20-29."
    ],
    
    realWorldImpact: "Implementation studies show 23% improvement in statin initiation appropriateness and 15% reduction in unnecessary statin prescribing when used as clinical decision support.",
    
    // Ongoing Maintenance & Monitoring
    monitoringProcess: "Quarterly performance monitoring using real-world EHR data. Automated alerts when AUROC drops below 0.70 or calibration slope deviates >15% from expected.",
    localDataValidity: "Currently Monitored",
    localDataValidityDesc: "Real-time monitoring across 127 health systems. Average local AUROC: 0.73 (range: 0.68-0.79)",
    
    fairnessMonitoringProcess: "Monthly stratified analysis by race, ethnicity, sex, and age groups. Automated bias detection using equalized odds and demographic parity metrics.",
    localFairnessData: "Under Review",
    localFairnessDataDesc: "Hispanic population showing 8% lower sensitivity compared to White population. Investigation ongoing.",
    
    updateProcess: "Annual model updates incorporating new population data. Emergency updates triggered if validity drops below threshold. Next major update: Q2 2025 incorporating 2020-2024 cohort data.",
    performanceCorrection: "Immediate deployment halt if AUROC <0.65 or fairness metrics show >20% disparities. Rollback to previous version within 24 hours. Root cause analysis within 72 hours.",
    
    currentMonitoringStatus: [
      "Last Performance Review: June 15, 2025 - Overall performance stable",
      "Known Issues: Calibration drift in Hispanic males age 60-79 under investigation",
      "Pending Updates: Integration of coronary artery calcium scoring planned for v3.0",
      "Alert Status: No critical alerts; 2 minor performance warnings under review"
    ],
    
    // Evidence Base & Clinical Guidelines
    primaryCitation: "Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.",
    supportingGuidelines: [
      "2019 AHA/ACC Primary Prevention Guidelines",
      "2018 AHA/ACC Cholesterol Management Guidelines",
      "2017 ACC/AHA Hypertension Guidelines"
    ],
    clinicalEvidenceLevel: "Class I, Level A",
    clinicalEvidenceLevelDesc: "Strong recommendation based on high-quality evidence",
    
    // Technical Implementation
    algorithmType: "Cox Proportional Hazards Model with race/sex-specific coefficients (Pooled Cohort Equations)",
    integrationMethod: "FHIR R4 Clinical Decision Support Service, HL7 CDS Hooks v1.0, SMART on FHIR v1.0",
    responseTime: "Mean: 847ms, 95th percentile: 1.2s",
    certificationDetails: "ONC Health IT Certification Program\nCriterion: 170.315(a)(9) Clinical Decision Support\nCertificate #: 15.07.07.3068.IC13.01.00.1.231204",
    
    // Contact Information
    clinicalSupport: "clinical.ai@cerner.com\n1-800-237-6371",
    technicalSupport: "integration.support@cerner.com\nDeveloper Portal: developer.cerner.com",
    regulatoryAffairs: "regulatory@cerner.com\nONC Certification ID: 3068",
    
    // Performance Metrics (from HTML Section 6)
    internalValidationMetrics: {
      aurocValidity: "0.76",
      fairnessScore: "0.81",
      fairnessScoreDesc: "Min subgroup AUROC",
      calibration: "Good",
      calibrationDesc: "Hosmer-Lemeshow p=0.12",
      sensitivity: "72.4%",
      specificity: "68.9%",
      ppv: "8.2%"
    },
    
    externalValidationMetrics: {
      aurocValidity: "0.71",
      aurocValidityDesc: "External Cohorts",
      fairnessScore: "0.68",
      fairnessScoreDesc: "Min External AUROC",
      calibration: "Fair",
      calibrationDesc: "Some overestimation",
      publishedStudies: "3",
      publishedStudiesDesc: "Published Studies on Clinical Outcomes"
    },
    
    outcomeEvaluationReferences: [
      "Muntner P, et al. 'Validation of the 2013 ACC/AHA pooled cohort risk equations.' JAMA. 2014;311(14):1406-1415.",
      "DeFilippis AP, et al. 'An analysis of calibration and discrimination among multiple cardiovascular risk scores.' Ann Intern Med. 2015;162(4):266-275.",
      "Yadlowsky S, et al. 'Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk.' Ann Intern Med. 2018;169(1):20-29."
    ],
    
    realWorldImpact: "Implementation studies show 23% improvement in statin initiation appropriateness and 15% reduction in unnecessary statin prescribing when used as clinical decision support.",
    
    // Ongoing Maintenance & Monitoring (from HTML Section 7)
    monitoringProcess: "Quarterly performance monitoring using real-world EHR data. Automated alerts when AUROC drops below 0.70 or calibration slope deviates >15% from expected.",
    localDataValidity: "Currently Monitored",
    localDataValidityDesc: "Real-time monitoring across 127 health systems. Average local AUROC: 0.73 (range: 0.68-0.79)",
    
    fairnessMonitoringProcess: "Monthly stratified analysis by race, ethnicity, sex, and age groups. Automated bias detection using equalized odds and demographic parity metrics.",
    localFairnessData: "Under Review",
    localFairnessDataDesc: "Hispanic population showing 8% lower sensitivity compared to White population. Investigation ongoing.",
    
    updateProcess: "Annual model updates incorporating new population data. Emergency updates triggered if validity drops below threshold. Next major update: Q2 2025 incorporating 2020-2024 cohort data.",
    performanceCorrection: "Immediate deployment halt if AUROC <0.65 or fairness metrics show >20% disparities. Rollback to previous version within 24 hours. Root cause analysis within 72 hours.",
    
    currentMonitoringStatus: [
      "Last Performance Review: June 15, 2025 - Overall performance stable",
      "Known Issues: Calibration drift in Hispanic males age 60-79 under investigation",
      "Pending Updates: Integration of coronary artery calcium scoring planned for v3.0",
      "Alert Status: No critical alerts; 2 minor performance warnings under review"
    ],
    
    // Evidence Base & Clinical Guidelines (from HTML Section 8)
    primaryCitation: "Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.",
    supportingGuidelines: [
      "2019 AHA/ACC Primary Prevention Guidelines",
      "2018 AHA/ACC Cholesterol Management Guidelines",
      "2017 ACC/AHA Hypertension Guidelines"
    ],
    clinicalEvidenceLevel: "Class I, Level A",
    clinicalEvidenceLevelDesc: "Strong recommendation based on high-quality evidence",
    
    // Footer Information
    lastUpdated: "July 30, 2025",
    modelCardVersion: "2.1.3",
    documentClassification: "For Healthcare Professional Use Only | HIPAA Compliant | 21st Century Cures Act Compliant"
  },
  ckd: {
    // Basic Information
    interventionName: "Cerner CKD Risk Assessment v1.8.2",
    developerName: "Oracle Cerner Corporation",
    developerContact: "Oracle Cerner Corporation\\n2800 Rockcreek Parkway, North Kansas City, MO 64117\\nEmail: clinical.ai@cerner.com\\nPhone: 1-800-237-6371",
    fundingSource: "Oracle Corporation internal R&D funding in collaboration with National Kidney Foundation",
    valueOutput: "5-year chronic kidney disease progression risk percentage with stage classification (Stage 1-5)",
    outputType: "Prediction & Risk Classification",
    complianceBadge: "✓ ONC HTI-1 Compliant | 21st Century Cures Act",
    
    // Purpose of Intervention
    intendedUse: "Early detection and monitoring of chronic kidney disease progression to inform treatment decisions and lifestyle modifications",
    intendedPatientPopulation: "Adults aged 18+ years at risk for or with early-stage chronic kidney disease presenting for primary care or nephrology evaluation",
    intendedUsers: "Licensed physicians, nurse practitioners, and physician assistants in primary care, nephrology, and endocrinology practices",
    decisionMakingRole: "Informs & Augments",
    decisionMakingDesc: "Provides clinical decision support to inform and augment clinician judgment; does not replace clinical decision-making",
    
    // Cautioned Out-of-Scope Use
    criticalAvoidances: [
      "Pediatric Populations: Not validated for patients under 18 years of age",
      "End-Stage Renal Disease: Not appropriate for patients already on dialysis",
      "Kidney Transplants: Not for kidney transplant recipients",
      "Acute Conditions: Not for use during acute kidney injury episodes",
      "Pregnancy: Not validated during pregnancy",
      "Emergency Settings: Not for use in emergency departments"
    ],
    knownRisks: [
      "Ethnic Variability: Performance may vary across ethnic subgroups",
      "Laboratory Dependency: Requires regular laboratory monitoring for accuracy",
      "Genetic Causes: May not capture rare genetic causes of CKD",
      "Fluctuating Function: Performance decreases with fluctuating kidney function",
      "Sole Decision-Making: Never use as the sole basis for treatment decisions",
      "Local Adaptation: May require local calibration for specific populations"
    ],
    
    // Development Details and Input Features
    trainingInclusion: "Adults 18+ years; Complete laboratory data; Minimum 5-year follow-up; US-based cohorts with diverse CKD stages",
    trainingExclusion: "End-stage renal disease at baseline; Missing critical lab values; Acute kidney injury episodes; Kidney transplant recipients",
    
    // USCDI v4 Data Elements
    uscdiElements: {
      race: { used: false, description: "White, Black/African American, Other, Native American" },
      ethnicity: { used: true, description: "Hispanic/Latino, Not Hispanic/Latino" },
      sex: { used: true, description: "Male, Female (biological sex at birth)" },
      dateOfBirth: { used: true, description: "For age calculation (18+ years)" },
      language: { used: false, description: "Not included in risk calculation" },
      sexualOrientation: { used: false, description: "Not included in risk calculation" },
      genderIdentity: { used: false, description: "Not included in risk calculation" },
      socialDeterminants: { used: true, description: "Socioeconomic status, insurance type" },
      healthAssessments: { used: true, description: "Diabetes status, hypertension status, cardiovascular history" }
    },
    
    // Demographic Representativeness
    demographicRepresentativeness: [
      { variable: "White Race", trainingData: "68.5%", usPopulation: "76.3%", representativeness: "Under-represented" },
      { variable: "Black/African American", trainingData: "28.2%", usPopulation: "13.4%", representativeness: "Over-represented" },
      { variable: "Hispanic/Latino", trainingData: "12.1%", usPopulation: "18.5%", representativeness: "Under-represented" },
      { variable: "Female Sex", trainingData: "52.3%", usPopulation: "50.8%", representativeness: "Good" },
      { variable: "Age 40-65", trainingData: "58.9%", usPopulation: "55.2%", representativeness: "Good" }
    ],
    
    relevanceToDeployedSetting: "Training data derived from nephrology clinics and primary care settings representative of US CKD patient populations. Geographic diversity includes urban and rural settings. Socioeconomic diversity adequate for healthcare settings.",
    
    fairnessApproach: "Race/ethnicity-specific thresholds developed. Enhanced focus on populations at higher CKD risk including African Americans and Native Americans with separate model calibration.",
    biasManagement: "Monthly fairness audits across demographic subgroups. Stratified analysis by race, ethnicity, sex, age, and diabetes status. Continuous monitoring for performance disparities in deployment.",
    
    // External Validation
    externalDataSources: "US Renal Data System (USRDS), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), National Health and Nutrition Examination Survey (NHANES)",
    clinicalSettings: "Nephrology clinics, primary care practices, endocrinology centers, integrated health systems across 18 US states",
    externalTestingParty: "Independent validation by National Kidney Foundation and American Society of Nephrology Clinical Research Committee",
    externalValidationProcess: "Prospective cohort validation with 5-year follow-up. Discrimination and calibration assessment across CKD stages. Real-world implementation studies in 8 health systems.",
    
    externalValidationDemographics: [
      { variable: "White Race", mesa: "52.1%", whi: "78.3%", regards: "61.2%" },
      { variable: "Black Race", mesa: "31.4%", whi: "12.8%", regards: "38.8%" },
      { variable: "Hispanic", mesa: "16.5%", whi: "5.2%", regards: "1.2%" },
      { variable: "Female", mesa: "56.2%", whi: "100%", regards: "58.4%" }
    ],
    
    // External Validation Sample Sizes
    externalValidationSampleSizes: {
      mesa: "5,243",
      whi: "7,156", 
      regards: "14,892"
    },
    
    // Performance Metrics
    internalValidationMetrics: {
      aurocValidity: "0.82",
      fairnessScore: "0.78",
      fairnessScoreDesc: "Min subgroup AUROC",
      calibration: "Good",
      calibrationDesc: "Hosmer-Lemeshow p=0.09",
      sensitivity: "78.6%",
      specificity: "74.2%",
      ppv: "15.3%"
    },
    
    externalValidationMetrics: {
      aurocValidity: "0.79",
      aurocValidityDesc: "External Cohorts",
      fairnessScore: "0.74",
      fairnessScoreDesc: "Min External AUROC",
      calibration: "Good",
      calibrationDesc: "Well-calibrated across stages",
      publishedStudies: "5",
      publishedStudiesDesc: "Published Studies on CKD Progression"
    },
    
    outcomeEvaluationReferences: [
      "Tangri N, et al. 'A predictive model for progression of chronic kidney disease to kidney failure.' JAMA. 2011;305(15):1553-1559.",
      "Grams ME, et al. 'Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.' Kidney Int. 2018;93(2):419-427.",
      "Nelson RG, et al. 'Development of risk prediction equations for incident chronic kidney disease.' JAMA. 2019;322(21):2104-2114."
    ],
    
    realWorldImpact: "Implementation studies show 31% improvement in early CKD detection and 22% reduction in progression to end-stage renal disease when used as clinical decision support.",
    
    // Ongoing Maintenance & Monitoring
    monitoringProcess: "Monthly performance monitoring using real-world EHR data. Automated alerts when AUROC drops below 0.75 or calibration slope deviates >12% from expected.",
    localDataValidity: "Currently Monitored",
    localDataValidityDesc: "Real-time monitoring across 95 health systems. Average local AUROC: 0.81 (range: 0.76-0.85)",
    
    fairnessMonitoringProcess: "Bi-weekly stratified analysis by race, ethnicity, sex, age, and diabetes status. Automated bias detection using equalized odds and demographic parity metrics.",
    localFairnessData: "Complete",
    localFairnessDataDesc: "All demographic groups showing consistent performance. No significant disparities detected in current deployment.",
    
    updateProcess: "Semi-annual model updates incorporating new CKD research and population data. Emergency updates triggered if validity drops below threshold. Next major update: Q1 2026 incorporating 2021-2025 cohort data.",
    performanceCorrection: "Immediate deployment halt if AUROC <0.70 or fairness metrics show >15% disparities. Rollback to previous version within 12 hours. Root cause analysis within 48 hours.",
    
    currentMonitoringStatus: [
      "Last Performance Review: July 15, 2025 - Performance stable across all metrics",
      "Known Issues: None currently identified",
      "Pending Updates: Integration of genetic risk factors planned for v2.0",
      "Alert Status: No alerts; all systems operating within normal parameters"
    ],
    
    // Evidence Base & Clinical Guidelines
    primaryCitation: "Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.",
    supportingGuidelines: [
      "2022 AKI and CKD in COVID-19 Consensus Conference Report",
      "2021 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD",
      "2020 KDIGO Clinical Practice Guideline for Diabetes Management in CKD"
    ],
    clinicalEvidenceLevel: "Class I, Level A",
    clinicalEvidenceLevelDesc: "Strong recommendation based on high-quality evidence from multiple RCTs",
    
    // Additional CKD-specific fields
    algorithmType: "Random Forest Classification Model with ensemble methods and feature importance ranking",
    integrationMethod: "FHIR R4 Clinical Decision Support Service, HL7 CDS Hooks v1.0, SMART on FHIR v1.0",
    responseTime: "Mean: 623ms, 95th percentile: 0.9s",
    certificationDetails: "ONC Health IT Certification Program\\nCriterion: 170.315(a)(9) Clinical Decision Support\\nCertificate #: 15.07.07.3069.IC13.01.00.1.231204",
    
    // Contact Information
    clinicalSupport: "clinical.ai@cerner.com\n1-800-237-6371",
    technicalSupport: "integration.support@cerner.com\nDeveloper Portal: developer.cerner.com",
    regulatoryAffairs: "regulatory@cerner.com\nONC Certification ID: 3069",
    
    // Footer Information
    lastUpdated: "July 30, 2025",
    modelCardVersion: "1.8.2",
    documentClassification: "For Healthcare Professional Use Only | HIPAA Compliant | 21st Century Cures Act Compliant",
    
    modelName: "Cerner CKD Risk Assessment",
    version: "v1.8.2",
    developer: "Oracle Cerner Corporation",
    releaseDate: "January 20, 2024",
    intendedUse: "Clinical decision support for chronic kidney disease progression risk assessment",
    certificationStatus: "ONC Certified Health IT Module (2025)",
    modelType: "Random Forest Classification Model",
    outputProvided: "5-year CKD progression risk with stage classification",
    endUsers: "Licensed clinicians using certified EHRs in nephrology and primary care",
    demographicsInputs: "Age (18+ years), Sex, Race/Ethnicity",
    laboratoryInputs: "Serum Creatinine, eGFR, Proteinuria, Blood Urea Nitrogen",
    clinicalInputs: "Blood Pressure, Body Mass Index",
    medicalHistoryInputs: "Diabetes Status, Hypertension Status, Heart Disease History",
    performanceMetrics: {
      auroc: "0.82",
      sensitivity: "78.6%",
      specificity: "74.2%",
      ppv: "15.3%",
      npv: "98.7%",
      calibration: "Good"
    },
    internalValidation: "Cross-validation on 35,000 patients from USRDS and CKD-EPI cohorts",
    externalValidation: "Validated on NHANES and Kaiser Permanente cohorts (n=25,000)",
    realWorldPerformance: "Deployed across 95+ health systems, continuous performance monitoring",
    targetUse: "Early detection and monitoring of chronic kidney disease progression",
    intendedPopulation: "Adults aged 18+ years at risk for or with early-stage CKD",
    clinicalSetting: "Primary care, nephrology clinics, endocrinology practices",
    exclusions: [
      "Patients under 18 years of age",
      "End-stage renal disease (ESRD) patients on dialysis",
      "Kidney transplant recipients",
      "Acute kidney injury episodes",
      "Pregnancy"
    ],
    limitations: [
      "Not for diagnosis or sole clinical decision-making",
      "Performance may vary by ethnic subgroups",
      "Requires regular laboratory monitoring for accuracy",
      "Clinical judgment must always override algorithmic recommendations",
      "May not capture rare genetic causes of CKD",
      "Performance decreases in patients with fluctuating kidney function"
    ],
    biasConsiderations: "Model performance varies across racial groups. Enhanced monitoring for Hispanic and Native American populations.",
    biasStatus: "Complete"
  },
  prostate: {
    // Basic Information
    interventionName: "Cerner Prostate Cancer Risk Assessment v3.0.1",
    developerName: "Oracle Cerner Corporation",
    developerContact: "Oracle Cerner Corporation\\n2800 Rockcreek Parkway, North Kansas City, MO 64117\\nEmail: clinical.ai@cerner.com\\nPhone: 1-800-237-6371",
    fundingSource: "Oracle Corporation internal R&D funding in collaboration with American Urological Association",
    valueOutput: "10-year prostate cancer risk percentage with screening recommendations (Low <2%, Intermediate 2-10%, High >10%)",
    outputType: "Prediction & Risk Classification",
    complianceBadge: "✓ ONC HTI-1 Compliant | 21st Century Cures Act",
    
    // Purpose of Intervention
    intendedUse: "Screening decision support and risk stratification for prostate cancer to inform shared decision-making",
    intendedPatientPopulation: "Men aged 45-75 years considering prostate cancer screening in primary care or urology settings",
    intendedUsers: "Licensed physicians, nurse practitioners, and physician assistants in primary care, urology, and preventive medicine practices",
    decisionMakingRole: "Informs & Augments",
    decisionMakingDesc: "Provides clinical decision support to inform and augment clinician judgment; does not replace clinical decision-making",
    
    // Cautioned Out-of-Scope Use
    criticalAvoidances: [
      "Age Limitations: Not for men under 45 or over 75 years of age",
      "Previous Cancer: Not appropriate for men with previous prostate cancer diagnosis",
      "Limited Life Expectancy: Not for men with life expectancy less than 10 years",
      "Screening Inability: Not for men unable to undergo screening procedures",
      "Active Infections: Not during active urinary tract infections",
      "Emergency Settings: Not for use in emergency departments"
    ],
    knownRisks: [
      "Guideline Variability: Screening guidelines vary by professional organizations",
      "Population-Based: Risk estimates are population-based, not individual predictions",
      "PSA Factors: PSA levels can be affected by various non-cancer factors",
      "Shared Decision-Making: Does not replace shared decision-making conversations",
      "Sole Decision-Making: Never use as the sole basis for screening decisions",
      "Local Adaptation: May require local calibration for specific populations"
    ],
    
    // Development Details and Input Features
    trainingInclusion: "Men 45-75 years; Complete PSA and clinical data; Minimum 10-year follow-up; US-based screening cohorts",
    trainingExclusion: "Previous prostate cancer diagnosis; Life expectancy <10 years; Unable to undergo screening; Active UTI during testing",
    
    // USCDI v4 Data Elements
    uscdiElements: {
      race: { used: true, description: "White, Black/African American, Asian, Other" },
      ethnicity: { used: true, description: "Hispanic/Latino, Not Hispanic/Latino" },
      sex: { used: true, description: "Male (biological sex at birth)" },
      dateOfBirth: { used: true, description: "For age calculation (45-75 years)" },
      language: { used: false, description: "Not included in risk calculation" },
      sexualOrientation: { used: false, description: "Not included in risk calculation" },
      genderIdentity: { used: false, description: "Not included in risk calculation" },
      socialDeterminants: { used: true, description: "Insurance status, geographic region" },
      healthAssessments: { used: true, description: "Family history, previous biopsy results" }
    },
    
    // Demographic Representativeness
    demographicRepresentativeness: [
      { variable: "White Race", trainingData: "71.8%", usPopulation: "76.3%", representativeness: "Good" },
      { variable: "Black/African American", trainingData: "18.5%", usPopulation: "13.4%", representativeness: "Over-represented" },
      { variable: "Hispanic/Latino", trainingData: "9.2%", usPopulation: "18.5%", representativeness: "Under-represented" },
      { variable: "Age 50-65", trainingData: "62.1%", usPopulation: "58.7%", representativeness: "Good" },
      { variable: "Age 45-49", trainingData: "15.3%", usPopulation: "16.8%", representativeness: "Good" }
    ],
    
    relevanceToDeployedSetting: "Training data derived from urology practices and primary care screening programs representative of US male populations. Geographic diversity includes all US regions. Enhanced representation of high-risk populations.",
    
    fairnessApproach: "Race-specific risk thresholds developed with enhanced focus on African American men who have higher prostate cancer risk. Separate screening recommendations by demographic subgroups.",
    biasManagement: "Monthly fairness audits across demographic subgroups. Stratified analysis by race, ethnicity, age, and family history. Enhanced monitoring for African American and Hispanic populations.",
    
    // External Validation
    externalDataSources: "Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Selenium and Vitamin E Cancer Prevention Trial (SELECT), European Randomized Study of Screening for Prostate Cancer (ERSPC)",
    clinicalSettings: "Urology practices, primary care clinics, men's health centers, academic medical centers across 22 US states and 8 international sites",
    externalTestingParty: "Independent validation by American Urological Association Clinical Guidelines Panel and European Association of Urology Research Foundation",
    externalValidationProcess: "Multi-national prospective validation with 10-year follow-up. Discrimination and calibration assessment across age and ethnic groups. Real-world screening studies in 12 health systems.",
    
    externalValidationDemographics: [
      { variable: "White Race", mesa: "68.4%", whi: "82.1%", regards: "74.2%" },
      { variable: "Black Race", mesa: "22.1%", whi: "8.3%", regards: "25.8%" },
      { variable: "Hispanic", mesa: "9.5%", whi: "4.2%", regards: "0.8%" },
      { variable: "Age 55-70", mesa: "78.9%", whi: "71.2%", regards: "82.1%" }
    ],
    
    // External Validation Sample Sizes
    externalValidationSampleSizes: {
      mesa: "4,127",
      whi: "6,892", 
      regards: "12,458"
    },
    
    // Performance Metrics
    internalValidationMetrics: {
      aurocValidity: "0.79",
      fairnessScore: "0.76",
      fairnessScoreDesc: "Min subgroup AUROC",
      calibration: "Good",
      calibrationDesc: "Hosmer-Lemeshow p=0.15",
      sensitivity: "81.2%",
      specificity: "69.8%",
      ppv: "12.7%"
    },
    
    externalValidationMetrics: {
      aurocValidity: "0.75",
      aurocValidityDesc: "External Cohorts",
      fairnessScore: "0.72",
      fairnessScoreDesc: "Min External AUROC",
      calibration: "Good",
      calibrationDesc: "Well-calibrated across sites",
      publishedStudies: "7",
      publishedStudiesDesc: "Published Studies on Screening Outcomes"
    },
    
    outcomeEvaluationReferences: [
      "Hugosson J, et al. 'A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.' Eur Urol. 2019;76(1):43-51.",
      "Pinsky PF, et al. 'Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.' Cancer. 2017;123(4):592-599.",
      "Roobol MJ, et al. 'A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.' Eur Urol. 2010;57(1):79-85."
    ],
    
    realWorldImpact: "Implementation studies show 28% reduction in unnecessary biopsies and 19% improvement in high-grade cancer detection when used as screening decision support.",
    
    // Ongoing Maintenance & Monitoring
    monitoringProcess: "Quarterly performance monitoring using real-world screening data. Automated alerts when AUROC drops below 0.72 or specificity falls below 65%.",
    localDataValidity: "Currently Monitored",
    localDataValidityDesc: "Real-time monitoring across 85 health systems. Average local AUROC: 0.77 (range: 0.71-0.82)",
    
    fairnessMonitoringProcess: "Monthly stratified analysis by race, ethnicity, age, and family history. Enhanced monitoring for screening disparities across demographic groups.",
    localFairnessData: "Complete",
    localFairnessDataDesc: "All demographic groups showing appropriate performance. Enhanced sensitivity maintained for African American men.",
    
    updateProcess: "Annual model updates incorporating new screening research and guideline changes. Emergency updates for major guideline revisions. Next major update: Q3 2025 incorporating new AUA guidelines.",
    performanceCorrection: "Immediate deployment halt if AUROC <0.70 or sensitivity for high-risk groups drops >10%. Rollback to previous version within 24 hours. Clinical review within 48 hours.",
    
    currentMonitoringStatus: [
      "Last Performance Review: July 22, 2025 - Performance stable across all demographics",
      "Known Issues: None currently identified",
      "Pending Updates: Integration of multiparametric MRI data planned for v4.0",
      "Alert Status: No alerts; optimal performance maintained"
    ],
    
    // Evidence Base & Clinical Guidelines
    primaryCitation: "Carter HB, et al. 'Early detection of prostate cancer: AUA Guideline.' J Urol. 2013;190(2):419-426.",
    supportingGuidelines: [
      "2023 AUA/SUO Guideline on Prostate Cancer Early Detection",
      "2022 NCCN Guidelines for Prostate Cancer Early Detection",
      "2021 EAU Guidelines on Prostate Cancer Screening"
    ],
    clinicalEvidenceLevel: "Class IIa, Level B",
    clinicalEvidenceLevelDesc: "Moderate recommendation based on limited evidence from screening trials",
    
    // Additional Prostate-specific fields
    algorithmType: "Gradient Boosting Machine Learning Model with ensemble methods and PSA kinetics integration",
    integrationMethod: "FHIR R4 Clinical Decision Support Service, HL7 CDS Hooks v1.0, SMART on FHIR v1.0",
    responseTime: "Mean: 734ms, 95th percentile: 1.1s",
    certificationDetails: "ONC Health IT Certification Program\\nCriterion: 170.315(a)(9) Clinical Decision Support\\nCertificate #: 15.07.07.3070.IC13.01.00.1.231204",
    
    // Contact Information
    clinicalSupport: "clinical.ai@cerner.com\n1-800-237-6371",
    technicalSupport: "integration.support@cerner.com\nDeveloper Portal: developer.cerner.com",
    regulatoryAffairs: "regulatory@cerner.com\nONC Certification ID: 3070",
    
    // Footer Information
    lastUpdated: "July 30, 2025",
    modelCardVersion: "3.0.1",
    documentClassification: "For Healthcare Professional Use Only | HIPAA Compliant | 21st Century Cures Act Compliant",
    
    modelName: "Cerner Prostate Cancer Risk Assessment",
    version: "v3.0.1",
    developer: "Oracle Cerner Corporation",
    releaseDate: "June 10, 2024",
    intendedUse: "Clinical decision support for prostate cancer screening risk stratification",
    certificationStatus: "ONC Certified Health IT Module (2026)",
    modelType: "Gradient Boosting Machine Learning Model",
    outputProvided: "10-year prostate cancer risk with screening recommendations",
    endUsers: "Licensed clinicians using certified EHRs in urology and primary care",
    demographicsInputs: "Age (45-75 years), Race/Ethnicity, Family History",
    laboratoryInputs: "PSA Level, Free PSA Ratio, PSA Velocity",
    clinicalInputs: "Digital Rectal Exam Results, Prostate Volume",
    medicalHistoryInputs: "Previous Biopsy Results, Medication History, Comorbidities",
    performanceMetrics: {
      auroc: "0.79",
      sensitivity: "81.2%",
      specificity: "69.8%",
      ppv: "12.7%",
      npv: "98.9%",
      calibration: "Good"
    },
    internalValidation: "Cross-validation on 42,000 patients from PLCO and SELECT trials",
    externalValidation: "Validated on European and Canadian screening cohorts (n=28,000)",
    realWorldPerformance: "Deployed across 85+ health systems, ongoing validation studies",
    targetUse: "Screening decision support and risk stratification for prostate cancer",
    intendedPopulation: "Men aged 45-75 years considering prostate cancer screening",
    clinicalSetting: "Primary care, urology practices, preventive medicine clinics",
    exclusions: [
      "Men under 45 or over 75 years of age",
      "Previous prostate cancer diagnosis",
      "Life expectancy less than 10 years",
      "Inability to undergo screening procedures",
      "Active urinary tract infections"
    ],
    limitations: [
      "Not for diagnosis or sole clinical decision-making",
      "Screening guidelines vary by professional organizations",
      "Risk estimates are population-based, not individual predictions",
      "Clinical judgment must always override algorithmic recommendations",
      "PSA levels can be affected by various factors",
      "Does not replace shared decision-making conversations"
    ],
    biasConsiderations: "Enhanced focus on African American men who have higher prostate cancer risk. Ongoing studies in diverse populations.",
    biasStatus: "Complete"
  },
  hospitalization: {
    // Basic Information
    interventionName: "Cerner Hospitalization Risk Assessment v2.3.4",
    developerName: "Oracle Cerner Corporation",
    developerContact: "Oracle Cerner Corporation\\n2800 Rockcreek Parkway, North Kansas City, MO 64117\\nEmail: clinical.ai@cerner.com\\nPhone: 1-800-237-6371",
    fundingSource: "Oracle Corporation internal R&D funding in collaboration with CMS and Hospital Quality Alliance",
    valueOutput: "30-day hospital readmission risk percentage with intervention recommendations (Low <10%, Moderate 10-25%, High >25%)",
    outputType: "Prediction & Risk Classification",
    complianceBadge: "✓ ONC HTI-1 Compliant | 21st Century Cures Act",
    
    // Purpose of Intervention
    intendedUse: "Post-discharge care planning and readmission prevention to improve patient outcomes and reduce healthcare costs",
    intendedPatientPopulation: "Adult patients being discharged from acute care hospitals with medical comorbidities",
    intendedUsers: "Licensed physicians, nurse practitioners, physician assistants, and care managers in hospital and ambulatory settings",
    decisionMakingRole: "Informs & Augments",
    decisionMakingDesc: "Provides clinical decision support to inform and augment clinician judgment; does not replace clinical decision-making",
    
    // Cautioned Out-of-Scope Use
    criticalAvoidances: [
      "Pediatric Populations: Not validated for patients under 18 years of age",
      "Psychiatric Admissions: Not for psychiatric admissions without medical comorbidities",
      "Planned Procedures: Not for planned readmissions for staged procedures",
      "End-of-Life Care: Not appropriate for hospice or comfort care patients",
      "Hospital Transfers: Not for transfers to other acute care facilities",
      "Emergency Settings: Not for emergency department use"
    ],
    knownRisks: [
      "Social Determinants: Social determinants data may be incomplete",
      "Hospital Variability: Performance varies by hospital type and patient population",
      "Data Dependency: Requires comprehensive EHR data for optimal performance",
      "Patient-Specific Factors: May not capture all patient-specific risk factors",
      "Sole Decision-Making: Never use as the sole basis for discharge decisions",
      "Local Adaptation: May require local calibration for specific hospital systems"
    ],
    
    // Development Details and Input Features
    trainingInclusion: "Adults 18+ years; Complete discharge data; Minimum 30-day follow-up; Multi-hospital cohorts with diverse case mix",
    trainingExclusion: "Psychiatric-only admissions; Planned readmissions; Hospice/comfort care; Transfers to other acute facilities; Pediatric cases",
    
    // USCDI v4 Data Elements
    uscdiElements: {
      race: { used: true, description: "White, Black/African American, Asian, Native American, Other" },
      ethnicity: { used: true, description: "Hispanic/Latino, Not Hispanic/Latino" },
      sex: { used: true, description: "Male, Female (biological sex at birth)" },
      dateOfBirth: { used: true, description: "For age calculation (18+ years)" },
      language: { used: true, description: "Primary language for discharge planning" },
      sexualOrientation: { used: false, description: "Not included in risk calculation" },
      genderIdentity: { used: false, description: "Not included in risk calculation" },
      socialDeterminants: { used: true, description: "Insurance status, housing stability, transportation access" },
      healthAssessments: { used: true, description: "Functional status, medication adherence, social support" }
    },
    
    // Demographic Representativeness
    demographicRepresentativeness: [
      { variable: "White Race", trainingData: "65.8%", usPopulation: "76.3%", representativeness: "Under-represented" },
      { variable: "Black/African American", trainingData: "22.4%", usPopulation: "13.4%", representativeness: "Over-represented" },
      { variable: "Hispanic/Latino", trainingData: "14.2%", usPopulation: "18.5%", representativeness: "Under-represented" },
      { variable: "Female Sex", trainingData: "55.7%", usPopulation: "50.8%", representativeness: "Good" },
      { variable: "Age 65+", trainingData: "48.9%", usPopulation: "16.5%", representativeness: "Over-represented" }
    ],
    
    relevanceToDeployedSetting: "Training data derived from academic medical centers, community hospitals, and safety-net hospitals representative of US inpatient populations. Geographic diversity includes urban and rural settings. Enhanced representation of high-readmission risk populations.",
    
    fairnessApproach: "Socioeconomic status-adjusted risk thresholds developed. Enhanced focus on populations with higher readmission risk including racial minorities and patients with social determinants barriers.",
    biasManagement: "Weekly fairness audits across demographic and socioeconomic subgroups. Stratified analysis by race, ethnicity, sex, age, insurance status, and social determinants. Continuous monitoring for health equity disparities.",
    
    // External Validation
    externalDataSources: "Centers for Medicare & Medicaid Services (CMS) Hospital Readmissions Reduction Program, Veterans Affairs (VA) Corporate Data Warehouse, Healthcare Cost and Utilization Project (HCUP)",
    clinicalSettings: "Academic medical centers, community hospitals, safety-net hospitals, critical access hospitals across all 50 US states and 4 international sites",
    externalTestingParty: "Independent validation by American Hospital Association Research Institute and CMS Innovation Center Healthcare Equity Research Team",
    externalValidationProcess: "Multi-site prospective validation with 30-day follow-up. Discrimination and calibration assessment across hospital types and patient populations. Real-world implementation studies in 15 health systems.",
    
    externalValidationDemographics: [
      { variable: "White Race", mesa: "58.2%", whi: "71.4%", regards: "63.8%" },
      { variable: "Black Race", mesa: "28.1%", whi: "15.2%", regards: "36.2%" },
      { variable: "Hispanic", mesa: "13.7%", whi: "8.4%", regards: "2.1%" },
      { variable: "Female", mesa: "57.3%", whi: "100%", regards: "59.8%" }
    ],
    
    // External Validation Sample Sizes
    externalValidationSampleSizes: {
      mesa: "8,964",
      whi: "9,847", 
      regards: "18,523"
    },
    
    // Performance Metrics
    internalValidationMetrics: {
      aurocValidity: "0.73",
      fairnessScore: "0.69",
      fairnessScoreDesc: "Min subgroup AUROC",
      calibration: "Fair",
      calibrationDesc: "Hosmer-Lemeshow p=0.08",
      sensitivity: "69.5%",
      specificity: "71.3%",
      ppv: "18.9%"
    },
    
    externalValidationMetrics: {
      aurocValidity: "0.71",
      aurocValidityDesc: "External Hospital Systems",
      fairnessScore: "0.66",
      fairnessScoreDesc: "Min External AUROC",
      calibration: "Fair",
      calibrationDesc: "Some overestimation in high-risk",
      publishedStudies: "4",
      publishedStudiesDesc: "Published Studies on Readmission Reduction"
    },
    
    outcomeEvaluationReferences: [
      "Kansagara D, et al. 'Risk prediction models for hospital readmission: a systematic review.' JAMA. 2011;306(15):1688-1698.",
      "Billings J, et al. 'Development of a predictive model to identify inpatients at risk of re-admission within 30 days of discharge (PARR-30).' BMJ Open. 2012;2(4):e001667.",
      "Burke RE, et al. 'Hospital readmission from post-acute care facilities: risk factors, timing, and outcomes.' J Am Geriatr Soc. 2016;64(4):715-722."
    ],
    
    realWorldImpact: "Implementation studies show 18% reduction in 30-day readmissions and 25% improvement in targeted discharge planning when used as clinical decision support.",
    
    // Ongoing Maintenance & Monitoring
    monitoringProcess: "Weekly performance monitoring using real-world readmission data. Automated alerts when AUROC drops below 0.68 or disparities in readmission rates exceed 15% between demographic groups.",
    localDataValidity: "Currently Monitored",
    localDataValidityDesc: "Real-time monitoring across 200 hospitals. Average local AUROC: 0.72 (range: 0.67-0.78)",
    
    fairnessMonitoringProcess: "Daily stratified analysis by race, ethnicity, sex, age, insurance status, and social determinants. Automated health equity monitoring with alerts for emerging disparities.",
    localFairnessData: "Active Monitoring",
    localFairnessDataDesc: "Enhanced monitoring showing improved equity outcomes. 12% reduction in readmission disparities between racial groups since implementation.",
    
    updateProcess: "Quarterly model updates incorporating new readmission patterns and CMS policy changes. Emergency updates for major healthcare policy changes. Next major update: Q4 2025 incorporating post-COVID readmission patterns.",
    performanceCorrection: "Immediate deployment halt if AUROC <0.65 or health equity metrics show >20% disparities. Rollback to previous version within 8 hours. Multidisciplinary review within 24 hours.",
    
    currentMonitoringStatus: [
      "Last Performance Review: July 25, 2025 - Performance stable with improved equity metrics",
      "Known Issues: Slight calibration drift in rural hospitals under investigation",
      "Pending Updates: Integration of social determinants scoring planned for v3.0",
      "Alert Status: 1 minor calibration alert for rural settings under review"
    ],
    
    // Evidence Base & Clinical Guidelines
    primaryCitation: "Medicare.gov Hospital Compare. Hospital Readmissions Reduction Program (HRRP). Centers for Medicare & Medicaid Services. Updated 2025.",
    supportingGuidelines: [
      "2024 AHA/ACC Scientific Statement on Hospital Readmissions",
      "2023 Society of Hospital Medicine Clinical Practice Guidelines",
      "2022 CMS Quality Payment Program Guidelines"
    ],
    clinicalEvidenceLevel: "Class IIa, Level B",
    clinicalEvidenceLevelDesc: "Moderate recommendation based on observational studies and quality improvement initiatives",
    
    // Additional Hospitalization-specific fields
    algorithmType: "Deep Learning Neural Network Model with attention mechanisms and social determinants integration",
    integrationMethod: "FHIR R4 Clinical Decision Support Service, HL7 CDS Hooks v1.0, SMART on FHIR v1.0",
    responseTime: "Mean: 892ms, 95th percentile: 1.4s",
    certificationDetails: "ONC Health IT Certification Program\\nCriterion: 170.315(a)(9) Clinical Decision Support\\nCertificate #: 15.07.07.3071.IC13.01.00.1.231204",
    
    // Contact Information
    clinicalSupport: "clinical.ai@cerner.com\n1-800-237-6371",
    technicalSupport: "integration.support@cerner.com\nDeveloper Portal: developer.cerner.com",
    regulatoryAffairs: "regulatory@cerner.com\nONC Certification ID: 3071",
    
    // Footer Information
    lastUpdated: "July 30, 2025",
    modelCardVersion: "2.3.4",
    documentClassification: "For Healthcare Professional Use Only | HIPAA Compliant | 21st Century Cures Act Compliant",
    
    modelName: "Cerner Hospitalization Risk Assessment",
    version: "v2.3.4",
    developer: "Oracle Cerner Corporation",
    releaseDate: "April 8, 2024",
    intendedUse: "Clinical decision support for 30-day hospital readmission risk assessment",
    certificationStatus: "ONC Certified Health IT Module (2025)",
    modelType: "Deep Learning Neural Network Model",
    outputProvided: "30-day readmission risk percentage with intervention recommendations",
    endUsers: "Licensed clinicians using certified EHRs in hospital and ambulatory settings",
    demographicsInputs: "Age, Sex, Race/Ethnicity, Insurance Status",
    laboratoryInputs: "Complete Blood Count, Basic Metabolic Panel, Liver Function Tests",
    clinicalInputs: "Vital Signs, Length of Stay, Discharge Disposition",
    medicalHistoryInputs: "Comorbidities, Previous Admissions, Medication Adherence, Social Determinants",
    performanceMetrics: {
      auroc: "0.73",
      sensitivity: "69.5%",
      specificity: "71.3%",
      ppv: "18.9%",
      npv: "96.2%",
      calibration: "Fair"
    },
    internalValidation: "Cross-validation on 150,000 hospital discharges from multi-site cohort",
    externalValidation: "Validated on CMS and VA hospital systems (n=75,000)",
    realWorldPerformance: "Deployed across 200+ hospitals, real-time monitoring and adjustment",
    targetUse: "Post-discharge care planning and readmission prevention",
    intendedPopulation: "Adult patients being discharged from acute care hospitals",
    clinicalSetting: "Inpatient units, discharge planning, care management, ambulatory follow-up",
    exclusions: [
      "Pediatric patients under 18 years",
      "Psychiatric admissions without medical comorbidities",
      "Planned readmissions for staged procedures",
      "Hospice or comfort care patients",
      "Transfers to other acute care facilities"
    ],
    limitations: [
      "Not for diagnosis or sole clinical decision-making",
      "Social determinants data may be incomplete",
      "Performance varies by hospital type and patient population",
      "Clinical judgment must always override algorithmic recommendations",
      "Requires comprehensive EHR data for optimal performance",
      "May not capture all patient-specific risk factors"
    ],
    biasConsiderations: "Active monitoring for disparities across socioeconomic and racial groups. Enhanced data collection for social determinants.",
    biasStatus: "Complete"
  }
};